Thrombus - 2004


A comparison of inpatient and community DVT management
Roland C Aldridge, Osahon A Gbinigie, Catherine A Hearnshaw and Graham D Johnson
pp 1-5
Deep vein thromboses (DVTs) are common, with an estimated annual incidence of one per 1000 population in the West. The goal of treatment is prevention of pulmonary embolism and recurrent DVT, with the restoration of venous patency and valvular function. Approximately 1–5% of patients with a DVT of the lower limb develop fatal pulmonary emboli. Traditionally, DVT patients were admitted to hospital and started on intravenous unfractionated heparin (UFH).
Comment: The problem of adverse drug reactions
Peter Rose
pp 2-2
One of my few recollections of the pharmacology course at medical school was being informed that one in nine hospital admissions were a direct result of the patient’s medication. It is interesting, therefore, to reflect on how many admissions to our hospitals are currently the result of adverse drug reactions. Has the situation changed over the years, in view of the resolve in the NHS to empower patients and provide them with detailed information of every possible drug side-effect? There is no doubt that patients continue to be admitted to our hospitals on a daily basis as a result of adverse drug reactions (ADRs).
Fighting thromboembolism in pregnancy – BCOG, Glasgow 2004
Shari Barber
pp 6-7
Preventing and treating thrombosis during pregnancy remains a major challenge today, despite dramatic improvements in maternal survival overall. This statement opened a symposium entitled ‘Experience with low molecular weight heparins in pregnancy’ at the 30th British Congress of Obstetrics and Gynaecology, held in Glasgow on 7–9 July. At a congress dominated by new research in areas such as genomics and stem cell therapy, this symposium attracted a large audience, reflecting the central importance of safe and effective anticoagulation in pregnancy.
Thrombosis in children Part 2: therapeutic options
Elene Psiachou-Leonard and Denise O’Shaughnessy
pp 8-10
In the second of our two articles on thrombosis in children, we will discuss the therapeutic options for primary or secondary thromboembolic disease (TED) in neonates and children. The treatment strategy is highly individualised in paediatric patients because of the current lack of appropriate and large clinical trials.1 In general, following thrombosis, immediate treatment aims at restoring blood flow to affected organs and subsequent normalisation of organ/tissue function. Subsequent treatment is instituted to prevent extension or recurrence of the thrombus. There are few indications for long-term anticoagulation prophylaxis in children.
Travel and thrombosis: advice to patients
Caroline Baglin
pp 11-11
The risk of blood clots triggered by travel and thrombosis has been given several different names over the last few years. It is now appropriately described as ‘traveller’s thrombosis’ instead of ‘economy class syndrome’; as thrombosis attributable to prolonged immobility also occurs in association with longdistance car, bus, rail and air travel. The longer the length of travel, the greater the risk.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Group Ltd and, together with the content, is bound by copyright. Copyright © 2018 Hayward Group Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)